DarioHealth (DRIO) Expected to Announce Quarterly Earnings on Monday

DarioHealth (NASDAQ:DRIO) is anticipated to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect DarioHealth to post earnings of ($1.57) per share and revenue of $5.0480 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

DarioHealth Trading Up 6.6%

Shares of DarioHealth stock opened at $11.97 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55. The company has a market capitalization of $80.92 million, a P/E ratio of -1.07 and a beta of 1.08. DarioHealth has a 1 year low of $5.93 and a 1 year high of $17.74. The company’s fifty day moving average is $11.28 and its two-hundred day moving average is $11.76.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on DRIO shares. TD Cowen reissued a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Finally, Stifel Nicolaus set a $16.00 price target on DarioHealth in a research note on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $38.00.

Institutional Trading of DarioHealth

Several hedge funds have recently modified their holdings of DRIO. Kestra Advisory Services LLC acquired a new position in DarioHealth during the fourth quarter worth $35,000. Geode Capital Management LLC lifted its holdings in DarioHealth by 167.9% in the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after acquiring an additional 31,063 shares during the period. Finally, XTX Topco Ltd boosted its position in shares of DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after purchasing an additional 43,513 shares in the last quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.